Chinese Hepatolgy ›› 2025, Vol. 30 ›› Issue (10): 1389-1392.

• Metabolic Associated Fatty Liver Disease • Previous Articles     Next Articles

Clinical efficacy of Ganzhi Formula in treating patients with chronic hepatitis B and metabolic-associated fatty liver disease

YU Xiao-xiao1, ZHOU Long1, SHEN Ying-qiu1, WANG Kai-xia1, WANG Tao1, LIU Cheng-hai2, QU Li-hong1, ZHANG Feng-di1   

  1. 1. Department of Infectious Disease, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China;
    2. Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese medicine (TCM), Shanghai 201203, China
  • Received:2024-10-10 Online:2025-10-31 Published:2025-12-16

PDF (PC)

3

Abstract: Objective To explore the efficacy of Ganzhi Formula in treatment of patients with CHB and MAFLD. Methods A total of 84 patients from the department of Liver Disease of Dongfang Hospital, Tongji University, who met the inclusion criteria CHB combined with MAFLD, were divided into the observation group and the control group with 42 cases in each group. The control group received NAs and polyene phosphatidyl choline, while the observation group received Ganzhi Formula based on the control group. Both groups received treatment for a total of 12 weeks. Liver imaging (FibroTouch liver stiffness LSM value, CAP value), liver serum enzymes, cholesterol levels, APRI, FIB-4, FAST, Agile, Chinese medicine syndrome, and other changes were collected. Results Following 12 weeks of treatment, the observation group's CAP efficiency was 52.4% (22/42) while the control group's was 31.0% (13/42). This difference was statistically significant (P=0.046). Compared to the control group, the observation group's effective rates of TCM evidence score and quality of life score were considerably higher at 83.3% (35/42) and 54.8% (23/42) compared to 40.4% (17/42) and 9.5% (4/42) in the control group (P<0.001). The FIB-4 score was improved in the observation group (1.23±0.49 vs 0.93±0.44,P=0.004). The levels of LDL in observation group was significantly lower than that of the control group [2.95(2.54, 3.17) vs 3.15 (2.67, 3.73), P=0.046]. There was no significant difference in liver function transaminases between the two groups before and after treatment (P>0.05). Conclusion Ganzhi Formula combined with NAs could significantly improve the CAP value, TCM evidence score, and blood lipid level of patients with CHB and MAFLD, suggesting its clinical application value.

Key words: Ganzhi Formula, Chronic viral hepatitis B, Metabolic-associated fatty liver disease, Clinical efficacy